专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014071352A3 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT 审中-公开
标题翻译：形成包含砷剂的基质的溶液和过程的配方
公开(公告)号：WO2014071352A3
公开(公告)日：2014-06-26
申请号：PCT/US2013068426
申请日：2013-11-05
申请人： DYNALOY LLC
发明人： HOCHSTETLER SPENCER ERICH , POLLARD KIMBERLY DONA , MOODY LESLIE SHANE , MACKENZIE PETER BORDEN , LIU JUNJIA
IPC分类号： H01L21/228
CPC分类号： C07F9/78 , C07F9/706 , H01L21/2225 , H01L21/228 , H01L29/66803
摘要： Formulations of solutions and processes are described to form a substrate including a dopant. In particular implementations, the dopant may include arsenic (As). In an embodiment, a dopant solution is provided that includes a solvent and a dopant. In a particular embodiment, the dopant solution may have a flashpoint that is at least approximately equal to a minimum temperature capable of causing atoms at a surface of the substrate to attach to an arsenic-containing compound of the dopant solution. In one embodiment, a number of silicon atoms at a surface of the substrate are covalently bonded to the arsenic-containing compound.
摘要翻译：描述溶液和工艺的配方以形成包含掺杂剂的基材。在特定的实施方式中，掺杂剂可以包括砷（As）。在一个实施例中，提供了包括溶剂和掺杂剂的掺杂剂溶液。在特定实施例中，掺杂剂溶液可具有至少近似等于能够使衬底表面处的原子附着至掺杂剂溶液的含砷化合物的最低温度的闪点。在一个实施方案中，衬底表面处的多个硅原子共价键合至含砷化合物。

2. 发明申请

WO2009043114A1 ARSENOXIDE COMPOUND AND METHOD OF USE 审中-公开
标题翻译：二氧化碳化合物及其使用方法
公开(公告)号：WO2009043114A1
公开(公告)日：2009-04-09
申请号：PCT/AU2008/001477
申请日：2008-10-03
申请人： NEWSOUTH INNOVATIONS PTY LIMITED , HOGG, Philip John , DILDA, Pierre
发明人： HOGG, Philip John , DILDA, Pierre
IPC分类号： C07F9/76 , A61K31/385 , A61K38/05 , A61K38/06 , A61P35/00 , C07C229/12 , C07K5/037 , C07K5/06 , C07K5/08
CPC分类号： C07F9/78 , A61K38/05 , A61K38/06 , C07K5/06 , C07K5/0606 , C07K5/06069 , C07K5/08
摘要： The present invention relates to organic arsenoxide compounds, pharmaceutical compositions comprising these compounds, and to their use in therapy, in particular treatment of proliferative diseases.
摘要翻译：本发明涉及有机砷化合物，包含这些化合物的药物组合物，以及它们在治疗中的用途，特别是治疗增殖性疾病。

3. 发明申请

WO2014071352A2 FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT 审中-公开
标题翻译：解决方案的制定和形成包含茜素甙的基材的方法
公开(公告)号：WO2014071352A2
公开(公告)日：2014-05-08
申请号：PCT/US2013/068426
申请日：2013-11-05
申请人： DYNALOY, LLC
发明人： HOCHSTETLER, Spencer, Erich , POLLARD, Kimberly, Dona , MOODY, Leslie, Shane , MACKENZIE, Peter, Borden , LIU, Junjia
IPC分类号： C07F9/78 , H01B1/12 , C07F9/70
CPC分类号： C07F9/78 , C07F9/706 , H01L21/2225 , H01L21/228 , H01L29/66803
摘要： Formulations of solutions and processes are described to form a substrate including a dopant. In particular implementations, the dopant may include arsenic (As). In an embodiment, a dopant solution is provided that includes a solvent and a dopant. In a particular embodiment, the dopant solution may have a flashpoint that is at least approximately equal to a minimum temperature capable of causing atoms at a surface of the substrate to attach to an arsenic-containing compound of the dopant solution. In one embodiment, a number of silicon atoms at a surface of the substrate are covalently bonded to the arsenic-containing compound.
摘要翻译：描述了溶液和方法的制剂以形成包括掺杂剂的衬底。在具体实施方案中，掺杂剂可以包括砷（As）。在一个实施例中，提供了包括溶剂和掺杂剂的掺杂剂溶液。在特定实施例中，掺杂剂溶液可以具有闪点，其至少近似等于能够使基底表面上的原子附着到掺杂剂溶液的含砷化合物的最低温度。在一个实施方案中，底物表面上的多个硅原子与含砷化合物共价键合。

4. 发明申请

WO2003107010A1 REAGENTS AND PROCEDURES FOR HIGH-SPECIFICITY LABELING 审中-公开
标题翻译：高特异性标签的试剂和程序
公开(公告)号：WO2003107010A1
公开(公告)日：2003-12-24
申请号：PCT/US2003/018792
申请日：2003-06-13
申请人： RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
发明人： EBRIGHT, Richard, H. , EBRIGHT, Yon, W.
IPC分类号： G01N33/68
CPC分类号： C07F9/78 , C07F9/706 , C07F9/806 , G01N33/533 , G01N33/582 , Y10S436/80
摘要： A molecule with two pendant phenylarsine moieties according to the general structural Formula (I) and tautomers, acids, and salts thereof, wherein: (i) Rl or R2, are each independently O-, S-, OR 3 or SR 3 with the provision that if either Rl or R2 is absent, the other remaining group is =0 or =S; or Rl and R2, together with the arsenic atom, form a ring according to one of the general structural Formulae (II), (III), (IV), or (V), wherein R3 is H, CH(OH)CH20H, or (CH2)y- Y, with q being 1-4 and Y being H, OH, NH2, SH, COOH, OAc, CONH2 or CN, and Z represents a hydrocarbon chain comprising 2-4 singly or doubly bonded carbon atoms each of which may be further substituted with one or more of hydrogen, methyl, ethyl, 1-propyl, 2-propyl, methoxy, hydroxy, amino, carboxy, sulfo, oxo, thio, halo (fluoro, chloro, bromo, or fluoro) and (CH2)„ "SO3, wherein n" is 1 or 2.
摘要翻译：具有根据一般结构式（I）的两个侧链胂基部分的分子和互变异构体，酸和其盐，其中：（i）R 1或R 2各自独立地为O，S-，OR 3或SR 3，其中规定如果R1或R2不存在，另一个剩余的基团为= 0或= S; 或者R 1和R 2与砷原子一起形成根据通式（II），（III），（IV）或（V）之一的环，其中R 3是H，CH（OH）CH 2 OH，或（CH2）y-Y，其中q为1-4，Y为H，OH，NH2，SH，COOH，OAc，CONH2或CN，Z表示包含2-4个单键或双键碳原子的烃链可以进一步被氢，甲基，乙基，1-丙基，2-丙基，甲氧基，羟基，氨基，羧基，磺基，氧代，硫代，卤代（氟，氯，溴或氟）中的一个或多个取代，和（CH 2）“”SO 3，其中n“为1或2。

5. 发明申请

WO2016061618A1 SELECTIVE TARGETING OF PROCOAGULANT PLATELETS 审中-公开
标题翻译：选择性定位程序平台
公开(公告)号：WO2016061618A1
公开(公告)日：2016-04-28
申请号：PCT/AU2015/000638
申请日：2015-10-26
申请人： NEWSOUTH INNOVATIONS PTY LIMITED
发明人： HOGG, Philip, John , CHEN, Viven, M.Y. , PASALIC, Leonardo , HUA, Vu, Minh
IPC分类号： C07F9/66 , C07F9/74 , C07F9/76 , C07F9/78 , A61K31/285
CPC分类号： A61K31/285 , A61K31/00 , C07F9/66 , C07F9/76 , C07F9/78 , G01N33/86 , G01N2500/04
摘要： The invention relates to a process for identifying procoagulant platelets both in vitro and in vivo, and the identification of compounds which selectively inhibit formation of procoagulant platelets.
摘要翻译：本发明涉及在体外和体内鉴定促凝血小板的方法，以及选择性抑制促凝血小板形成的化合物的鉴定。

6. 发明申请

WO2004042079A1 INDUCTION OF THE MITOCHONDRIAL PERMEABILITY TRANSITION 审中-公开
标题翻译：诱导麻醉渗透性过渡
公开(公告)号：WO2004042079A1
公开(公告)日：2004-05-21
申请号：PCT/AU2003/001483
申请日：2003-11-07
申请人： UNISEARCH LIMITED , HOGG, Philip, John
发明人： HOGG, Philip, John
IPC分类号： C12Q1/68
CPC分类号： C07K7/06 , A61K31/285 , C07F5/06 , C07F9/78 , C07F9/803 , C07F9/82 , C07K5/06 , C07K5/08 , G01N33/5011 , G01N33/5079 , G01N33/574 , G01N33/6872 , G01N2333/515 , G01N2500/10
摘要： The present invention relates to process for identifying a compound which induces the mitochondrial permeability transition (MPT) in proliferating cells, wherein said process comprises contacting a cell or cell extract with a compound, determining whether the compound binds to adenine nucleotide translocator (ANT), and determining whether the compound selectively induces the MPT in proliferating cells.
摘要翻译：本发明涉及用于鉴定在增殖细胞中诱导线粒体通透性转换（MPT）的化合物的方法，其中所述方法包括使细胞或细胞提取物与化合物接触，确定化合物是否结合腺嘌呤核苷酸转运体（ANT），以及确定所述化合物是否在增殖细胞中选择性诱导MPT。

7. 发明申请

WO01021628A1 A SUBSTANTIALLY CELL MEMBRANE IMPERMEABLE COMPOUND AND USE THEREOF 审中-公开
标题翻译：主要细胞膜不可复制的化合物及其用途
公开(公告)号：WO01021628A1
公开(公告)日：2001-03-29
申请号：PCT/AU2000/001143
申请日：2000-09-20
IPC分类号： A61K38/00 , A61P1/04 , A61P3/10 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/10 , A61P9/14 , A61P17/00 , A61P17/02 , A61P19/02 , A61P21/04 , A61P25/28 , A61P27/02 , A61P29/00 , A61P31/12 , A61P31/14 , A61P31/18 , A61P35/00 , A61P35/02 , A61P37/00 , A61P41/00 , A61P43/00 , C07F9/78 , C07F9/80 , C07K5/037 , C07F9/20 , C07F9/74
CPC分类号： C07F9/72 , C07F9/78 , C07F9/803
摘要： The present invention relates to a compound according to Formula (I): A-(L-Y)p, wherein A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and/or spacer group; Y comprises at least one arsenoxide or arsenoxide equivalent; p is an integer from 1 to 10; and the sum total of carbon atoms in A and L together, is greater than 6.
摘要翻译：本发明涉及式（I）的化合物：A-（L-Y）p，其中A包含至少一个基本上为细胞膜不可渗透的侧基; L包含任何合适的接头和/或间隔基团; Y包含至少一种等同的砷或砷; p是1至10的整数; 并且A和L中的碳原子总数在一起，大于6。

8. 发明申请

WO1995015941A1 ARYL SUBSTITUTED AMINO ACIDS, CNS INFLUENCING AGENTS 审中-公开
标题翻译： ARYL替代氨基酸，CNS影响剂
公开(公告)号：WO1995015941A1
公开(公告)日：1995-06-15
申请号：PCT/GB1994002689
申请日：1994-12-09
申请人： UNIVERSITY OF BRISTOL , TOCRIS COOKSON LIMITED , WATKINS, Jeffrey, Clifton , JANE, David, Edward , BRISE, Ewan, Fraser
发明人： UNIVERSITY OF BRISTOL , TOCRIS COOKSON LIMITED
IPC分类号： C07C229/36
CPC分类号： C07C229/38 , C07C229/36 , C07C229/50 , C07C2601/02 , C07C2601/08 , C07F9/304 , C07F9/306 , C07F9/3834 , C07F9/3882 , C07F9/74 , C07F9/76 , C07F9/78
摘要： Compounds of formula (I) are disclosed, wherein: Ar is an aromatic group having up to 10 carbon atoms substituted by at least one substituent selected from hydroxy, carboxy, phosphono, -PO2H(OR ), phosphinico, -PO2H(R ), -OPO3H2, -OPO2H(OR ), arsono, -AsO2H(OR ), arsinico, -AsO2H(R ), tetrazolyl, sulpho, sulphino, sulpheno, thio, -OSO3H and -(CR R )qY, where Y is carboxy, phosphono, -PO2H(OR ), phosphinico, -PO2H(R ), -OPO3H2, -OPO2H(OR ), arsono, -AsO2H(OR ), arsinico, -AsO2H(R ), tetrazolyl, sulpho, sulphino, sulpheno, -OSO3H and R and R are the same or different and are selected from hydrogen, C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alkynyl or halo or R and R together constitute an oxo group, q is an integer from 0 to 3; Ar being optionally further substituted by one or more substituents selected from fluoro, chloro, bromo, iodo, nitro, cyano, C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alkynyl, haloalkyl (such as trifluoromethyl), aryl or azido; R is hydrogen, C1 to C6 alkyl, C2 to C6 alkenyl or C2 to C6 alkynyl, aryl, aralkyl, biaryl or C3 to C8 cycloalkyl, haloalkyl or hydroxyalkyl; R , R , R and R are the same or different and are selected from hydrogen, C1 to C6 alkyl, C2 to C6 alkenyl and C2 to C6 alkynyl; R is C1 to C6 alkyl, C2 to C6 alkenyl, C2 to C6 alkynyl, aryl, aralkyl, biaryl or C3 to C8 cycloalkylene; Q is carboxy, C1 to C6 alkoxycarbonyl, aminocarbonyl, C1 to C6 alkylaminocarbonyl or hydroxamic acid; and p is an integer form 0 to 3; R and R , R and Ar, R and Ar, R and Ar and R and NR R optionally being linked to form a carbocyclic ring and pharmaceutically acceptable acid or base addition salts thereof. The compounds may be used as agents to influence the central nervous system.
摘要翻译：公开了式（I）的化合物，其中：Ar是具有至多10个碳原子的芳基，被至少一个选自羟基，羧基，膦酰基，-PO2H（OR 6），亚磷酰基，-PO2H（ R 6），-OPO 3 H 2，-OPO 2 H（OR 6），arsono，-AsO 2 H（OR 6），亚硫酰基，-AsO 2 H（R 6），四唑基，磺基， -OSO 3 H和 - （CR 7 R 8）q Y，其中Y是羧基，膦酰基，-PO2H（OR 6），亚磷酰基，-PO2H（R6），-OPO3H2，-OPO2H （OR 6），亚砷基，-AsO 2 H（R 6），四唑基，磺基，亚磺酰基，磺基，-OSO 3 H和R 7和R 8相同或不同，并且选自氢，C1至C6烷基，C2至C6烯基，C2至C6炔基或卤素或R 7和R 8一起构成氧代基，q为0至3的整数; Ar任选进一步被一个或多个选自氟，氯，溴，碘，硝基，氰基，C 1至C 6烷基，C 2至C 6烯基，C 2至C 6炔基，卤代烷基（例如三氟甲基），芳基或叠氮基的取代基取代。 R 3是氢，C 1至C 6烷基，C 2至C 6烯基或C 2至C 6炔基，芳基，芳烷基，联芳基或C 3至C 8环烷基，卤代烷基或羟烷基; R 1，R 2，R 4和R 5相同或不同，并且选自氢，C 1至C 6烷基，C 2至C 6烯基和C 2至C 6炔基; R 6是C 1 -C 6烷基，C 2至C 6烯基，C 2至C 6炔基，芳基，芳烷基，联芳基或C 3至C 8亚环烷基; Q为羧基，C1至C6烷氧基羰基，氨基羰基，C1至C6烷基氨基羰基或异羟肟酸; p为0〜3的整数; R 1和R 2，R 3和Ar，R 1和Ar，R 2和Ar和R 3和NR 4 R 5任选被连接形成碳环和其药学上可接受的酸或碱加成盐。该化合物可用作影响中枢神经系统的药剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式